Production of the new "solution" for DNA or RNA vaccines
Vaccines using the Nanotaxi® technology
Nucleic acid vaccination is an attractive method that has seen renewed global interest over the last couple of years but gene gun or electroporation cannot achieve stellar immunity in human patients.
Nanotaxi® technology allows very efficient vaccination as it delivers not only very efficiently the target antigen, but also highly activates the danger sensors in the body.
In-Cell-Art offers turnkey vaccine solutions thanks to its Nanotaxi® technology.
The company is able (i) to synthetize DNA or RNA molecules from an identified target whose in silico sequence is available on databases and (ii) to associate it with the Nanotaxi® for delivery into the cells. The Nanotaxi® crosses the cell membrane and delivers safely the DNA or RNA molecules into the cells in a controlled manner.
The cells both synthesize the antigen and activate the innate immune system for the efficient production of antibodies and cytotoxic T lymphocytes. The DNA or RNA molecules express the antigen that automatically leads to the desired immune response.
A revolutionary administration method
In-Cell-Art develops vaccines using Nanotaxi® technology. Conventional methods are used for administration:
- No pain for the patient
- High transfection and vaccination efficiency by controlling the delivery mechanism
Proven efficiency of ICA vaccines in liver cancers
An anti-tumor vaccine developed by In-Cell-Art using the ICA614 Nanotaxi® was tested successfully to treat hepatocellular carcinoma (HCC) on a highly relevant mouse model of human HCC.
In-Cell-Art associated DNA, encoding the tumor antigen (alpha-fetoprotein) and the ICA614 Nanotaxi®.
The results demonstrated the efficiency of the vaccine, as all multi-nodular hepatocellular carcinoma were destroyed in the vaccinated mice.